Haploidentical donor the donor of choice in the treatment of relapse Hodgkin’s lymphoma

Introduction. Modern treatment of Hodgkin?s lymphoma has led to a cure in 60-90% patients. The problem are patients whom disease relapse occurs, or the is refractory initial therapy. standard application high-dose chemotherapy with autologous stem cell transplantation. However, about half experience failure after Despite new therapeutic modalities, relapses, so allogeneic transplantation method choice further treatment. Haploidentical - yes/no. donor for an transplant can be related unrelated human leukocyte associated antigen-matched haploidentical related. Allogeneic used because strong effect graft against lymphoma. dilemmas whether compared related/unrelated matched better and when treating presented this paper. Conclusion. still only potentially curative option treat In order outcome as good possible, it necessary precisely define pre-transplant conditioning, well selection donor. Randomized multicenter studies provide answers all doubts.